GlassScriptPhysician profile
Natalia Cameron
NPI 1063935963
$2,332.74
in general payments reported to CMS, 2019-2025
17 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,120 · 2024: $855 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.84 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $194.98 | 2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $157.74 | 2023-2024 | Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $156.26 | 2024 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $144.72 | 2023 | Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $114.75 | 2023-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $104.95 | 2023-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $97.81 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.63 | 2023-2024 | Caplyta |
| Almatica Pharma LLC | $74.26 | 2023-2024 | Gralise, Loreev Xr |
| Alkermes, INC. | $35.11 | 2023 | Aristada, Lybalvi |
| Corium, LLC | $28.71 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $21.05 | 2023 | Jornay Pm |
| Noven Therapeutics, LLC | $20.89 | 2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $20.65 | 2023 | Belsomra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.05 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $13.34 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.